menu
    • menu
    [{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"AllianceRx Walgreens","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Cysteamine Hydrochloride","moa":"Glutathione synthase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Leadiant Biosciences \/ AllianceRx Walgreens","highestDevelopmentStatusID":"15","companyTruncated":"Leadiant Biosciences \/ AllianceRx Walgreens"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cysteamine Hydrochloride","moa":"Glutathione synthase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cysteamine Hydrochloride","moa":"Glutathione synthase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Cysteamine HCl

    Menu

    Cysteamine HCl

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Leadiant Biosciences

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Leadiant Biosciences

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cysteamine Hydrochloride

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : AllianceRx Walgreens

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            AllianceRx Walgreens Prime Relaunches Exclusive Partnership for the Distribution of Cystaran® (cysteamine oph...

                            Details : As an exclusive partner, AllianceRx Walgreens Prime is able to offer end-to-end solutions for Leadiant Biosciences and Cystaran patients. Cystaran, a topical ophthalmic therapy for the treatment of corneal cystine crystals in patients with cystinosis.

                            Product Name : Cystaran

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 22, 2022

                            Lead Product(s) : Cysteamine Hydrochloride

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : AllianceRx Walgreens

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Recordati Rare Diseases

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Recordati Rare Diseases

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cysteamine Hydrochloride

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            U.S. FDA Approves CYSTADROPS® (Cysteamine Ophthalmic Solution) 0.37%, A New Practical Treatment Option for th...

                            Details : Cystadrops (cysteamine) ophthalmic solution, acts as a cystine-depleting agent by converting cystine to cysteine and is indicated for the treatment of corneal cystine crystal deposits in adults and children with cystinosis.

                            Product Name : Cystadrops

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 25, 2020

                            Lead Product(s) : Cysteamine Hydrochloride

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Recordati Rare Diseases

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Recordati Rare Diseases

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cysteamine Hydrochloride

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            U.S. FDA Approves CYSTADROPS® 0.37%, A New Practical Treatment Option for the Ocular Manifestations of Cystin...

                            Details : CYSTADROPS demonstrated a significant reduction in cystine crystal deposits in the cornea of the eye and is the first and only FDA-approved cysteamine drop formulation with four times a day dosing.

                            Product Name : Cystadrops

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 25, 2020

                            Lead Product(s) : Cysteamine Hydrochloride

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth